Back to Search
Start Over
Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study.
- Source :
-
Clinical cardiology [Clin Cardiol] 2017 Apr; Vol. 40 (4), pp. 210-215. Date of Electronic Publication: 2016 Nov 24. - Publication Year :
- 2017
-
Abstract
- Background: Inflammation has a key role in the process of atherosclerosis. Production of leukotrienes by 5-lipoxygenase has been linked to atherosclerotic plaques and cardiovascular events.<br />Hypothesis: In this study, a selective 5-LO inhibitor will slow plaque progression using serial cardiac computed tomographic angiography (CCTA).<br />Methods: Patients with recent acute coronary syndrome (ACS) were prospectively assigned to one of 3 VIA-2291 doses (25 mg, 50 mg, 100 mg) or placebo by oral administration. All groups underwent CCTA at baseline and at 6 months' follow-up. Plaque types such as low-attenuation plaque (LAP), fibro-fatty tissue (FF), fibro-calcified plaque (FC), and dense calcium plaque (DC) were measured based upon predefined density threshold, and changes from baseline CCTA were analyzed.<br />Results: The final analysis included 54 patients (age, 56 ± 9 years; 85.1% male) with CCTA at baseline and 24 weeks. Evaluating on treatment VIA-2291 (all 3 doses, n = 37) demonstrated significant reductions in plaque progression compared with placebo (n = 17). VIA-2291 significantly reduced LAP (5.9 ± 20.7 mm <superscript>3</superscript> vs -9.7 ± 33.3 mm <superscript>3</superscript> ), FF (11.1 mm <superscript>3</superscript> ± 13.3 mm <superscript>3</superscript> vs -0.9 ± 2.7 mm <superscript>3</superscript> ), and FC (-0.1 ± 6.22 mm <superscript>3</superscript> vs -14.3 ± 6.2 mm <superscript>3</superscript> ; all P < 0.05) and retarded the progression of DC (3.9 ± 3.2 mm <superscript>3</superscript> vs 0.2 ± 0.4 mm <superscript>3</superscript> ) compared with placebo.<br />Conclusions: VIA-2291 resulted in slowed plaque progression compared with placebo across different plaque subtypes in patients with recent ACS (http://ClinicalTrials.gov NCT00358826).<br /> (© 2016 Wiley Periodicals, Inc.)
- Subjects :
- Acute Coronary Syndrome diagnosis
Acute Coronary Syndrome etiology
Adult
Aged
Aged, 80 and over
Disease Progression
Dose-Response Relationship, Drug
Follow-Up Studies
Humans
Hydroxyurea administration & dosage
Lipoxygenase Inhibitors administration & dosage
Middle Aged
Plaque, Atherosclerotic complications
Plaque, Atherosclerotic diagnosis
Prospective Studies
Time Factors
Treatment Outcome
Acute Coronary Syndrome drug therapy
Computed Tomography Angiography methods
Coronary Vessels diagnostic imaging
Hydroxyurea analogs & derivatives
Multidetector Computed Tomography methods
Plaque, Atherosclerotic drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1932-8737
- Volume :
- 40
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinical cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 27883201
- Full Text :
- https://doi.org/10.1002/clc.22646